Minerva Surgical, Inc. (UTRS) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Minerva Surgical, Inc. (UTRS) trades at $0.0001 with AI Score 43/100 (Grade C). Minerva Surgical, Inc. focuses on developing and commercializing minimally invasive solutions for women's uterine healthcare needs in the United States. Sector: Healthcare.
Price as of Jul 23, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for UTRS: UTRS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates UTRS against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
UTRS: 2/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Minerva Surgical, Inc. (UTRS) Healthcare & Pipeline Overview
Minerva Surgical, Inc. provides minimally invasive solutions for uterine healthcare, including endometrial ablation and tissue removal systems. Targeting the U.S. market, the company serves hospitals, ambulatory surgical centers, and physician offices. It competes with other medical device companies in the women's health sector.
What Is the Investment Thesis for UTRS?
Minerva Surgical operates in the women's health medical device market, which presents both opportunities and challenges. The company's focus on minimally invasive solutions aligns with current trends in healthcare, potentially driving adoption of its products. However, the company's negative profit margin of -67.8% indicates significant challenges in achieving profitability. With a market cap of $0.00B and a high beta of 4.60, Minerva Surgical exhibits high volatility. Potential investors should carefully consider the company's financial performance and competitive landscape. Growth catalysts may include expanding market share and new product development, while risks include competition and regulatory hurdles.
Based on FMP financials and quantitative analysis
UTRS Key Highlights
- Minerva Surgical operates with 174 employees, indicating a relatively small scale of operations.
- The company's gross margin stands at 54.2%, suggesting a reasonable level of efficiency in production and sales.
- The company's market capitalization is $0.00B, indicating a very small company size.
- The company's profit margin is -67.8%, indicating significant losses.
- The stock exhibits a high beta of 4.60, suggesting high volatility relative to the market.
Who Are UTRS's Competitors?
UTRS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CMHSF Comprehensive Healthcare Systems, Inc. | $0.34 | +0.00% | $6.22M | 55 |
| CRBKF Carebook Technologies Inc. | $0.03 | +0.00% | $6.84M | 64 |
| CMPD CompuMed, Inc. | $6.70 | -0.30% | $8.64M | 60 |
| BBLN Babylon Holdings Limited | $0.55 | -13.99% | $14.1M | 56 |
| THKKF Think Research Corporation | $0.23 | -1.74% | $17.8M | 57 |
| AKLI Akili, Inc. | $0.43 | +0.25% | $34.1M | 67 |
| VRHI Veri Medtech Holdings Inc. | $2.00 | +0.00% | $40.0M | 67 |
| AIRDF Rocket Doctor AI Inc. | $0.45 | +2.62% | $43.6M | 56 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are UTRS's Key Strengths?
- Specialized focus on uterine healthcare.
- Portfolio of minimally invasive solutions.
- Established presence in the U.S. market.
- Proprietary technology in endometrial ablation.
What Are UTRS's Weaknesses?
- Negative profit margin.
- Limited market capitalization.
- High beta indicating high volatility.
- Dependence on a niche market.
What Could Drive UTRS Stock Higher?
- Expansion of sales and marketing efforts to increase product adoption.
- Potential regulatory approvals for new products or indications.
- Strategic partnerships with hospitals and clinics.
- Development of next-generation medical devices.
What Are the Key Risks for UTRS?
- Financial-distress signal — its Altman Z-Score of -6.27 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Competition from established medical device companies.
- Regulatory hurdles and compliance requirements.
- Technological obsolescence.
- Economic downturn affecting healthcare spending.
- Negative profit margin and financial instability.
What Are the Growth Opportunities for UTRS?
- Expansion of Product Portfolio: Minerva Surgical can expand its product portfolio by developing and commercializing new devices and technologies for uterine healthcare. This includes addressing unmet clinical needs and targeting specific patient populations. Timeline: 2-3 years.
- Geographic Expansion: Minerva Surgical can expand its geographic reach beyond the United States by entering international markets. This includes targeting countries with growing healthcare expenditures and a demand for minimally invasive procedures. The global market for women's health devices is expected to grow at a CAGR of 5-7% over the next five years. Timeline: 3-5 years.
- Strategic Partnerships: Minerva Surgical can form strategic partnerships with hospitals, clinics, and physician groups to increase adoption of its products. This includes offering training programs, marketing support, and bundled solutions. Such partnerships can provide access to a wider customer base and enhance brand awareness. Timeline: Ongoing.
- Regulatory Approvals: Securing regulatory approvals for new products and indications is crucial for Minerva Surgical's growth. This includes obtaining FDA clearance in the United States and similar approvals in other countries. Successful regulatory outcomes can expand the company's market access and competitive advantage. Timeline: Ongoing.
- Technological Innovation: Investing in research and development to drive technological innovation is essential for Minerva Surgical to maintain its competitive edge. This includes developing next-generation devices with improved performance, safety, and ease of use. The market for innovative medical technologies is constantly evolving, requiring continuous investment in R&D. Timeline: Ongoing.
What Opportunities Does UTRS Have?
- Expansion into international markets.
- Development of new products and technologies.
- Strategic partnerships with healthcare providers.
- Growing demand for minimally invasive procedures.
What Threats Does UTRS Face?
- Competition from established medical device companies.
- Regulatory hurdles and compliance requirements.
- Technological obsolescence.
- Economic downturn affecting healthcare spending.
What Are UTRS's Competitive Advantages?
- Proprietary technology in endometrial ablation and tissue removal.
- Established relationships with obstetrician-gynecologists.
- Focus on minimally invasive solutions.
What Does UTRS Do?
Minerva Surgical, Inc., established in 2008 and headquartered in Santa Clara, California, is a commercial-stage medical technology company dedicated to addressing women's uterine healthcare needs through minimally invasive solutions. The company develops, manufactures, and commercializes a range of devices designed for use by obstetrician-gynecologists in various medical settings. Minerva Surgical's product portfolio includes the Minerva ES Endometrial Ablation System and the Genesys HTA Endometrial Ablation System, both designed for endometrial ablation procedures. Additionally, the company offers the Symphion Tissue Removal System, a minimally invasive system combining bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring. The Resectr Tissue Resection Device, a handheld surgical instrument, is also part of their offerings, enabling the hysteroscopic removal and diagnosis of endometrial polyps. These products are utilized in hospitals, ambulatory surgical centers, and physician offices across the United States, reflecting the company's focus on providing versatile solutions for uterine healthcare.
What Products and Services Does UTRS Offer?
- Develops minimally invasive solutions for uterine healthcare.
- Manufactures endometrial ablation systems.
- Commercializes tissue removal systems.
- Offers the Minerva ES Endometrial Ablation System.
- Provides the Genesys HTA Endometrial Ablation System.
- Offers the Symphion Tissue Removal System.
- Provides the Resectr Tissue Resection Device.
How Does UTRS Make Money?
- Develops and manufactures medical devices for uterine healthcare.
- Sells products to hospitals, ambulatory surgical centers, and physician offices.
- Generates revenue through direct sales of its devices.
What Industry Does UTRS Operate In?
Minerva Surgical operates within the medical device industry, specifically focusing on women's health. This sector is characterized by ongoing innovation and technological advancements aimed at improving patient outcomes and reducing invasiveness of procedures. The competitive landscape includes established players and emerging companies offering similar or alternative solutions for uterine healthcare. Market trends indicate a growing demand for minimally invasive procedures, driven by patient preferences and healthcare provider adoption. Minerva Surgical's success depends on its ability to differentiate its products, navigate regulatory pathways, and effectively compete in this dynamic environment.
Who Are UTRS's Key Customers?
- Hospitals
- Ambulatory surgical centers
- Physician offices
- Obstetrician-gynecologists
Minerva Surgical, Inc. (UTRS) Valuation Context
Relative to its peer group, UTRS's quantitative score of 43/100 is below the peer average of 58/100.
Key Financial Metrics
Return on assets is -49.5%, showing how much profit it generates from its asset base. A current ratio of 2.53 indicates the company holds enough short-term assets to cover its near-term obligations.
F-Score 2/9Financial Health
Minerva Surgical, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -6.27 places it in the distress zone, a signal of elevated financial risk.
UTRS Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Specialized focus on uterine healthcare.
- Portfolio of minimally invasive solutions.
- Established presence in the U.S. market.
- Proprietary technology in endometrial ablation.
Bear Case
- Negative profit margin.
- Limited market capitalization.
- High beta indicating high volatility.
- Dependence on a niche market.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
UTRS Latest News
No recent news available for UTRS.
UTRS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for UTRS.
Price Targets
Wall Street price target analysis for UTRS.
UTRS MoonshotScore
What does this score mean?
The MoonshotScore rates UTRS 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Darin Hammers
CEO
Darin Hammers serves as the CEO of Minerva Surgical, Inc. His background includes extensive experience in the medical device industry, with a focus on commercializing innovative technologies. Prior to joining Minerva Surgical, he held leadership positions at various medical device companies, overseeing sales, marketing, and product development. His expertise lies in driving market adoption of new medical devices and building strong relationships with healthcare providers. He is responsible for managing 174 employees.
Track Record: Under Darin Hammers' leadership, Minerva Surgical has focused on expanding its product portfolio and increasing market penetration in the U.S. The company has navigated regulatory challenges and continued to commercialize its minimally invasive solutions for uterine healthcare. Key milestones include securing regulatory approvals for new products and expanding the company's sales network.
UTRS OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Minerva Surgical may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries a higher degree of risk compared to those listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited financial disclosure
- Low trading volume and liquidity
- Wide bid-ask spreads
- Higher potential for price manipulation
- Increased risk of fraud or mismanagement
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Review any available news articles or press releases about the company.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- Check for any regulatory actions or legal proceedings involving the company.
- Company has a registered business address and contact information.
- Management team has relevant experience in the medical device industry.
- Company has patents or other intellectual property related to its products.
- Company has a website with detailed information about its products and services.
- Company's products are used by healthcare providers in the United States.
UTRS Healthcare Stock FAQ
What does the AI Score mean for UTRS?
UTRS holds an AI Score of 43/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Minerva Surgical, Inc. focuses on developing and commercializing minimally invasive solutions for women's uterine healthcare needs in the United States. Their product portfolio includes endometrial …
What does Minerva Surgical, Inc. do?
Minerva Surgical, Inc. is a medical technology company that develops, manufactures, and commercializes minimally invasive solutions for women's uterine healthcare needs. Their product portfolio includes endometrial ablation systems like Minerva ES and Genesys HTA, as well as tissue removal systems such as Symphion and Resectr.
What are the main risks for UTRS?
Minerva Surgical faces several key risks, including intense competition from larger, more established medical device companies. Regulatory hurdles and compliance requirements pose ongoing challenges, particularly in obtaining approvals for new products and indications. The company's financial performance, characterized by a negative profit margin, raises concerns about its long-term sustainability. Additionally, technological obsolescence and economic downturns affecting healthcare spending could negatively impact the company's growth prospects.
What are the key factors to evaluate for UTRS?
Minerva Surgical, Inc. (UTRS) holds an AI score of 43/100 (low). Not financial advice.
How frequently does UTRS data refresh on this page?
UTRS's price was last updated on Jul 23, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven UTRS's recent stock price performance?
Minerva Surgical, Inc. (UTRS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized focus on uterine healthcare. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider UTRS overvalued or undervalued right now?
Minerva Surgical, Inc. (UTRS) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research UTRS before investing?
Before investing in Minerva Surgical, Inc. (UTRS), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding UTRS to a portfolio?
Key strength of Minerva Surgical, Inc. (UTRS): Specialized focus on uterine healthcare. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- OTC market data may be limited or delayed.
- AI analysis is pending and may provide additional insights.